(Q37801266)

23 August 2017

BRCA mutations in the management of breast cancer: the state of the art. (English)

1 reference

23 August 2017

1 reference

1

Steven A Narod

1 reference

PubMed ID

20956982

23 August 2017

language of work or name

English

0 references

publication date

19 October 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

12

1 reference

23 August 2017

702-707

1 reference

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Identification of the breast cancer susceptibility gene BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The contribution of founder mutations to early-onset breast cancer in French-Canadian women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The contribution of founder mutations in BRCA1 to breast cancer in Belarus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The effect of a single BRCA2 mutation on cancer in Iceland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

A high frequent BRCA1 founder mutation identified in the Greenlandic population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

A high proportion of founder BRCA1 mutations in Polish breast cancer families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The development of interval breast malignancies in patients with BRCA mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Early detection of breast and ovarian cancer in families with BRCA mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy inBRCA1/2-Associated Stage I/II Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Triple-negative breast cancer: clinical features and patterns of recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Ovarian cancer and hormone replacement therapy in the Million Women Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Risk reducing mastectomy: outcomes in 10 European centres.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

31 March 2020

12 December 2020

Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Fine tuning chemotherapy to match BRCA1 status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.166

Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging

31 March 2020

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

1 reference

12 December 2020

Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes

1 reference

12 December 2020

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

1 reference

12 December 2020

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin

1 reference

12 December 2020

10.1038/NRCLINONC.2010.166

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20956982